Compare NOMD & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOMD | LTGO |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2026 |
| Metric | NOMD | LTGO |
|---|---|---|
| Price | $11.48 | $14.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $13.74 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 1.2M | 359.3K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | ★ 6.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.99 | $13.85 |
| 52 Week High | $13.08 | $25.93 |
| Indicator | NOMD | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | 35.48 |
| Support Level | $10.99 | $14.60 |
| Resistance Level | $12.16 | $16.56 |
| Average True Range (ATR) | 0.30 | 1.25 |
| MACD | 0.12 | -0.18 |
| Stochastic Oscillator | 83.45 | 24.46 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.